Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company”), a healthcare company developing and commercializing precision ...
Researchers found that people with atrial fibrillation had lower MRI-based glymphatic activity and poorer cognitive ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) ...
SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for ...
New DXComply capability enables enterprises to enforce consent and preference policies across websites and mobile apps ...
Farmers may struggle to access Defra’s £225m Capital Grants scheme after key advisers warned they are already unable to take on new requests as part of ...
Researchers link glymphatic system (brain waste-clearance) dysfunction in childhood to the future development of psychosis and chemical imbalances.
Biofluid proteomics revealed distinct inflammatory signatures in Alzheimer’s patients with fast vs slow tau progression.
Earlier detection and treatment optimization enabled by CNSide may reduce overall LM-related healthcare costs by ~40% (33%-47%) Potential savings are driven by earlier therapeutic intervention, ...
US FDA approves Denali Therapeutics’ Avlayah for treatment of Hunter syndrome: South San Francisco, California Denali Therapeutics Inc., ...
MedPage Today on MSN
FDA Signals Regulatory Flexibility With Accelerated Approval of Rare Disease Drug
Tividenofusp alfa is the first approved treatment for neurologic complications of Hunter s ...
Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results